Last reviewed · How we verify

AG-881 — Competitive Intelligence Brief

AG-881 (AG-881) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oncology. Area: Oncology.

phase 1 Oncology TET2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AG-881 (AG-881) — Agios Pharmaceuticals, Inc.. Tet methylcytosine dioxygenase 2 (TET2) inhibitor

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AG-881 TARGET AG-881 Agios Pharmaceuticals, Inc. phase 1 Oncology TET2
TACE with Drug Eluting Beads procedure TACE with Drug Eluting Beads procedure Ain Shams University marketed Interventional oncology procedure / chemoembolization

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oncology class)

  1. Agios Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AG-881 — Competitive Intelligence Brief. https://druglandscape.com/ci/ag-881. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: